GlassScriptPhysician profile
Stephen W Askins
NPI 1528088762
$4,275.05
in general payments reported to CMS, 2019-2025
39 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $539 · 2021: $767 · 2022: $407 · 2023: $847 · 2024: $722 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,328.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $571.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $493.13 | 2020-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $426.47 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.55 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $199.16 | 2020-2022 | |
| Abbott Laboratories | $179.07 | 2023-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $170.38 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.15 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $156.12 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Amgen INC. | $146.96 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $132.93 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $128.02 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $121.29 | 2023-2024 | Gvoke Hypopen, Keveyis |
| Amarin Pharma, INC. | $119.90 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $111.15 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.58 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $63.70 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $56.72 | 2022-2025 | |
| Exact Sciences Corporation | $55.50 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $53.97 | 2019-2020 | |
| Mylan Specialty L.P. | $52.49 | 2019-2021 | |
| Allergan, INC. | $51.53 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $46.65 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $46.60 | 2021-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $43.76 | 2025 | Zoryve |
| Dexcom, INC. | $39.20 | 2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $38.88 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.26 | 2025 | Caplyta |
| Renalytix Ai, INC. | $34.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.12 | 2022 | |
| Scilex Pharmaceuticals INC. | $24.19 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $21.80 | 2023 | Austedo |
| Antares Pharma, INC. | $17.89 | 2023 | Nocdurna, Tlando, Xyosted |
| Genentech USA, INC. | $17.40 | 2019 | |
| Ardelyx, INC. | $17.28 | 2025 | Ibsrela |
| Axsome Therapeutics, INC. | $14.45 | 2025 | Auvelity |
| Edwards Lifesciences Corporation | $14.17 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Eisai INC. | $13.57 | 2021 | |
| Adlon Therapeutics L.P. | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Askins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.